As per DelveInsight’s analysis, the Osteosarcoma therapeutic market in the 7MM was estimated to be USD 72.50 million in 2017 and is further expected to increase modestly in the forecast period 2020-30.
Several clinical trials are ongoing in the Osteosarcoma market. The companies in the Osteosarcoma market are primarily focusing on tackling the issues of drug-resistance, which is the major reason behind the failure of presently available adjuvant chemos in the Osteosarcoma treatment.
Worldwide, some of the key companies such as Eisai, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GSK, Novartis, AADi Bioscience, Eleison Pharmaceuticals, Aurora BioPharma, BioAtla, Iovance Biotherapeutics, Bristol Myers Squibb, Cellestia Biotech are actively engaged in producing desirable pipeline therapies.
For more details on Osteosarcoma Therapeutics Market, visit: https://www.delveinsight.com/blog/osteosarcoma-market-key-pharma-companies/